# C3 Reduct (Curcuminoid metabolite)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/c3-reduct
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Tetrahydrocurcumin, THC, Tetrahydrodiferuloylmethane, Reduced curcumin, Colorless curcumin, Hydrogenated curcuminoid, Curcumin metabolite

## Overview

C3 Reduct is a reduced curcuminoid metabolite derived from Curcumin C3 Complex, composed primarily of tetrahydrocurcumin, tetrahydrodemethoxycurcumin, and tetrahydrobisdemethoxycurcumin. It exerts antioxidant and [anti-inflammatory](/ingredients/condition/inflammation) effects by scavenging [reactive oxygen species](/ingredients/condition/antioxidant) and modulating NF-κB signaling, with potentially superior bioavailability compared to native curcuminoids.

## Health Benefits

• No direct clinical evidence exists for C3 Reduct itself - all human trials identified were on related Curcumin C3 Complex
• Parent compound shows modest [anti-inflammatory](/ingredients/condition/inflammation) effects in metabolic diseases (evidence quality: moderate from RCTs)
• Preliminary evidence for reducing mesothelioma cell tumorigenicity through impaired self-renewal (evidence quality: preliminary, in-vitro only)
• Parent curcumin showed limited efficacy for psoriasis with only 16.7% response rate in one small RCT (evidence quality: weak)
• Anti-inflammatory effects on IL-6 and anti-dsDNA markers in SLE suggested for curcuminoids (evidence quality: preliminary)

## Mechanism of Action

C3 Reduct's primary active component, tetrahydrocurcumin, inhibits NF-κB pathway activation by suppressing IκB kinase (IKK) phosphorylation, thereby reducing downstream transcription of [pro-inflammatory cytokine](/ingredients/condition/inflammation)s such as TNF-α, IL-1β, and IL-6. Tetrahydrocurcumin also directly scavenges [reactive oxygen species](/ingredients/condition/antioxidant) (ROS) via its phenolic hydroxyl groups, exhibiting stronger free-radical quenching activity than parent curcumin in some in vitro models. Additionally, it may modulate Nrf2-Keap1 signaling to upregulate endogenous antioxidant enzymes including superoxide dismutase (SOD) and catalase.

## Clinical Summary

No published human clinical trials have been conducted specifically on C3 Reduct as an isolated ingredient; existing evidence is extrapolated from studies on its parent compound, Curcumin C3 Complex, and on tetrahydrocurcumin individually. RCTs on Curcumin C3 Complex involving 40–120 participants have demonstrated modest reductions in CRP and IL-6 levels in patients with metabolic syndrome and osteoarthritis, with effect sizes generally considered moderate. In vitro and animal studies on tetrahydrocurcumin suggest superior [antioxidant](/ingredients/condition/antioxidant) potency and improved plasma half-life compared to curcumin, but these findings have not been confirmed in adequately powered human trials. The overall evidence base for C3 Reduct specifically remains preliminary, and efficacy claims should be interpreted with caution until dedicated clinical data are available.

## Nutritional Profile

C3 Reduct is a specialized curcuminoid metabolite preparation, not a whole food ingredient, and therefore lacks conventional macronutrient or micronutrient content in the traditional dietary sense. Its bioactive identity centers on reduced (hydrogenated) curcuminoid derivatives: primarily tetrahydrocurcumin (THC), tetrahydrodemethoxycurcumin, and tetrahydrobisdemethoxycurcumin — the three principal reduced analogs corresponding to the curcuminoids found in Curcumin C3 Complex. Tetrahydrocurcumin typically constitutes the dominant fraction (~75-80% of total reduced curcuminoids by weight in standardized preparations). These compounds are colorless, in contrast to parent curcuminoids, due to saturation of the conjugated double-bond system in the heptadienedione backbone. Protein, fat, carbohydrate, fiber, and micronutrient content are negligible or absent as supplied in extract/supplement form. Bioavailability: tetrahydrocurcumin demonstrates meaningfully improved oral bioavailability relative to native curcumin, attributed to greater metabolic stability (resistance to phase I oxidative [metabolism](/ingredients/condition/weight-management)) and enhanced intestinal absorption; animal pharmacokinetic data suggest 4-10x higher plasma AUC compared to equivalent curcumin doses, though robust human pharmacokinetic trials specifically on C3 Reduct branding are limited. The reduced compounds retain phenolic hydroxyl groups relevant to [antioxidant activity](/ingredients/condition/antioxidant) (DPPH radical scavenging capacity documented in vitro). No caloric contribution is nutritionally meaningful at typical supplemental doses (250-500 mg range).

## Dosage & Preparation

No clinically studied dosages for C3 Reduct have been established. Related Curcumin C3 Complex studies used: 4.5g/day for psoriasis, 300mg/day for metabolic conditions. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

C3 Reduct is generally considered safe at doses comparable to curcuminoid supplementation (500–2000 mg/day of the parent complex), with the most common adverse effects being mild gastrointestinal symptoms including nausea, loose stools, and bloating. Because tetrahydrocurcumin may inhibit CYP3A4 and P-glycoprotein, clinically relevant interactions with anticoagulants such as warfarin, immunosuppressants like tacrolimus, and chemotherapy agents are theoretically possible and warrant medical supervision. C3 Reduct should be used cautiously in individuals with gallbladder disease, as curcuminoids can stimulate bile secretion and potentially exacerbate obstruction. Pregnant and breastfeeding women should avoid supplemental doses beyond dietary levels due to insufficient safety data.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on C3 Reduct (tetrahydrocurcumin) were identified in the research. Evidence is limited to studies on the parent compound Curcumin C3 Complex, including a psoriasis RCT (n=12, terminated early for insufficient efficacy), an Alzheimer's trial (n=36, no efficacy data provided), and metabolic disease RCTs using 150mg twice daily.

## Historical & Cultural Context

C3 Reduct lacks traditional use as it is a modern branded metabolite. The parent compound curcumin from turmeric has approximately 4,000 years of history in Ayurveda for [inflammation](/ingredients/condition/inflammation), [digestion](/ingredients/condition/gut-health), skin disorders, and wound healing.

## Synergistic Combinations

Piperine (Bioperine), Phospholipids, Black pepper extract, Omega-3 fatty acids, Quercetin

## Frequently Asked Questions

### What is the difference between C3 Reduct and Curcumin C3 Complex?

Curcumin C3 Complex is a standardized blend of three curcuminoids — curcumin, demethoxycurcumin, and bisdemethoxycurcumin — derived from turmeric root. C3 Reduct is the reduced (hydrogenated) form of this blend, yielding tetrahydrocurcumin, tetrahydrodemethoxycurcumin, and tetrahydrobisdemethoxycurcumin, which lack the conjugated double bonds of the parent molecules. This structural change is associated with increased chemical stability, altered metabolism, and potentially stronger radical-scavenging capacity compared to the native curcuminoids.

### Is tetrahydrocurcumin better absorbed than curcumin?

Preliminary pharmacokinetic studies in rodents suggest tetrahydrocurcumin achieves higher peak plasma concentrations (Cmax) and a longer half-life than native curcumin following oral administration, possibly due to reduced first-pass conjugation. However, robust comparative bioavailability data in humans are lacking, and factors such as formulation, fat co-ingestion, and piperine addition significantly influence absorption of both compounds. Until well-controlled human pharmacokinetic trials are published, superiority claims about absorption should be considered speculative.

### What are the anti-inflammatory benefits of C3 Reduct?

C3 Reduct's anti-inflammatory activity is primarily attributed to tetrahydrocurcumin inhibiting IκB kinase (IKK), which prevents NF-κB nuclear translocation and reduces transcription of TNF-α, IL-1β, and COX-2. In vitro studies have shown tetrahydrocurcumin can suppress LPS-induced inflammatory markers in macrophage cell lines at concentrations of 10–50 µM. No direct human RCTs exist for C3 Reduct, so clinical magnitude of these effects in humans remains unquantified.

### Can C3 Reduct interact with blood thinners like warfarin?

Yes, a theoretical drug interaction exists between C3 Reduct and anticoagulants such as warfarin, because curcuminoids and their reduced metabolites can inhibit platelet aggregation and may inhibit CYP2C9, the primary enzyme responsible for warfarin metabolism. Inhibition of CYP2C9 could elevate warfarin plasma levels and increase bleeding risk. Patients on anticoagulant or antiplatelet therapy should consult a physician before using C3 Reduct supplements and consider INR monitoring if co-administration is deemed appropriate.

### What dosage of C3 Reduct is typically used in supplements?

Because no dedicated clinical trials define an evidence-based dose for C3 Reduct specifically, manufacturers typically use doses ranging from 250 mg to 1000 mg per serving, often mirroring dosing protocols established for Curcumin C3 Complex in RCTs. Studies on Curcumin C3 Complex have used 500–1500 mg/day divided into two or three doses, frequently combined with 5–10 mg piperine to enhance bioavailability by up to 20-fold. Optimal dosing for C3 Reduct will require dedicated pharmacokinetic and efficacy trials before evidence-based recommendations can be established.

### Is C3 Reduct safe during pregnancy and breastfeeding?

Safety data specifically for C3 Reduct during pregnancy and breastfeeding is limited, as clinical trials have not been conducted in these populations. While the parent compound curcumin has traditional use in some cultures, pregnant and nursing women should consult a healthcare provider before supplementing with C3 Reduct due to insufficient evidence of safety in these sensitive periods.

### How strong is the clinical evidence supporting C3 Reduct?

C3 Reduct itself lacks direct human clinical trials; all available evidence is extrapolated from studies on Curcumin C3 Complex, which shows moderate-quality evidence for anti-inflammatory effects in metabolic diseases. Additionally, preliminary in-vitro research suggests potential benefits for mesothelioma cell inhibition, but this requires substantial further research before any clinical claims can be made.

### Who should avoid C3 Reduct supplementation?

Individuals taking anticoagulant medications like warfarin should avoid C3 Reduct without medical supervision due to potential interaction risk. Additionally, those with curcumin allergies, active bleeding disorders, or planned surgery should consult a healthcare provider, as the curcuminoid metabolite may have similar contraindications to its parent compound.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*